Scholar Rock (NASDAQ:SRRK) Downgraded by Wolfe Research to “Peer Perform”

Scholar Rock (NASDAQ:SRRK) was downgraded by Wolfe Research from an “outperform” rating to a “peer perform” rating in a report issued on Thursday, Briefing.com reports.

Several other equities research analysts have also recently commented on the stock. BMO Capital Markets boosted their price target on shares of Scholar Rock from $76.00 to $84.00 and gave the stock an “outperform” rating in a research report on Monday, September 14th. Barclays cut Scholar Rock from an “overweight” rating to a “cautious” rating in a report on Tuesday, September 15th. Citigroup raised their price objective on Scholar Rock from $60.00 to $74.00 and gave the company a “buy” rating in a report on Monday, September 14th. Truist Financial lifted their target price on Scholar Rock from $76.00 to $77.00 and gave the company a “buy” rating in a research report on Thursday, September 24th. Finally, HC Wainwright upped their target price on Scholar Rock from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, September 15th. Three investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $67.67.

Scholar Rock Stock Performance

Shares of SRRK stock opened at $46.60 on Thursday. Scholar Rock has a 12 month low of $29.35 and a 12 month high of $61.76. The company’s fifty day simple moving average is $46.64 and its 200-day simple moving average is $48.23. The firm has a market cap of $5.68 billion, a PE ratio of -13.87 and a beta of 0.78. The company has a quick ratio of 7.02, a current ratio of 7.02 and a debt-to-equity ratio of 0.77.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Tuesday, November 10th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. The business had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.30 million. During the same period last year, the business posted ($0.90) EPS. Equities research analysts expect that Scholar Rock will post -3.29 EPS for the current fiscal year.

Insider Buying and Selling at Scholar Rock

In other news, Director Srinivas Akkaraju bought 146,970 shares of the firm’s stock in a transaction that occurred on Monday, October 26th. The stock was acquired at an average cost of $41.59 per share, with a total value of $6,112,482.30. Following the completion of the purchase, the director owned 6,380,517 shares of the company’s stock, valued at $265,365,702.03. This represents a 2.36% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 10.30% of the company’s stock.

Institutional Trading of Scholar Rock

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC grew its position in shares of Scholar Rock by 20.8% in the 2nd quarter. GAMMA Investing LLC now owns 1,406 shares of the company’s stock valued at $77,000 after acquiring an additional 242 shares during the period. Nisa Investment Advisors LLC raised its holdings in shares of Scholar Rock by 28.1% in the 3rd quarter. Nisa Investment Advisors LLC now owns 2,618 shares of the company’s stock valued at $127,000 after purchasing an additional 574 shares during the period. Syon Capital LLC lifted its stake in Scholar Rock by 6.4% in the 2nd quarter. Syon Capital LLC now owns 9,782 shares of the company’s stock valued at $538,000 after purchasing an additional 588 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in Scholar Rock by 92.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,270 shares of the company’s stock valued at $62,000 after purchasing an additional 610 shares during the last quarter. Finally, Allworth Financial LP acquired a new stake in Scholar Rock in the 2nd quarter valued at about $35,000. 91.08% of the stock is owned by institutional investors.

Key Scholar Rock News

Here’s some of the latest news about SRRK:

• Positive Sentiment: HC Wainwright raised its Q4 2026 EPS forecast to a loss of $0.75 from $0.78 and its FY2026 forecast to a loss of $3.23 from $3.30. The firm maintained its Buy rating and $70 price target. Analyst outlook
• Positive Sentiment: Scholar Rock’s Q3 loss of $0.81 per share was narrower than the cited consensus estimate, and the company reported its first product revenue—potentially signaling early commercial progress. Q3 results
• Negative Sentiment: HC Wainwright sharply reduced EPS estimates for FY2027–FY2030: its FY2027 loss estimate increased to $2.66 from $1.95, and it moved FY2029 from projected earnings of $0.47 to a loss of $0.12. Its FY2030 profit estimate was cut to $1.00 from $1.44. These weaker longer-term expectations may weigh on the outlook despite the retained Buy rating.

About Scholar Rock

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-β) superfamily, which plays roles in processes including muscle development and immune regulation. The company’s lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients’ motor function.